Laboratory of Translational Immunology, Italy; Humanitas Clinical and Research Center - IRCCS - Rozzano, MI, Italy.
Laboratory of Mucosal Immunology and Microbiota, Italy; Humanitas Clinical and Research Center - IRCCS - Rozzano, MI, Italy; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, MI, Italy.
Semin Cancer Biol. 2021 Jul;72:90-101. doi: 10.1016/j.semcancer.2020.05.019. Epub 2020 May 31.
Cancer immunotherapy has witnessed a new renaissance with the advent of immune checkpoint inhibitors, which reactivate T cells and foster endogenous anti-tumor responses. The excellent results of immunotherapy in the field of melanoma, renal cancer, lung cancer, and other cancer types that have traditionally been known to be immunogenic, rekindled the interest of the oncology community in extending the benefits to all cancers including breast cancer (BC). In this review, we highlight the current state of using T cells as both markers for clinical practice and therapeutic options for BC.
癌症免疫疗法随着免疫检查点抑制剂的出现迎来了新的复兴，这些抑制剂可以激活 T 细胞并促进内源性抗肿瘤反应。免疫疗法在黑色素瘤、肾癌、肺癌等传统上被认为具有免疫原性的癌症类型中的出色结果，重新激发了肿瘤学界将这些益处扩展到包括乳腺癌 (BC) 在内的所有癌症的兴趣。在这篇综述中，我们强调了将 T 细胞用作临床实践的标志物和 BC 治疗选择的现状。
